The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Anticoagulation during extracorporeal membrane oxygenation (ECMO) usually is required to prevent thrombosis. The aim of this study was to investigate the usefulness of nafamostat mesilate (NM) as a regional anticoagulant during veno-arterial ECMO (VA-ECMO) treatment. Methods: We retrospectively reviewed the medical records of 16 patients receiving VA-ECMO and NM from January 2017 to June 2020 at Haeundae Paik Hospital. We compared clinical and laboratory data, including activated partial thromboplastin time (aPTT), which was measured simultaneously in patients and the ECMO site, to estimate the efficacy of regional anticoagulation. Results: The median patient age was 68.5 years, and 56.3% of patients were men. Cardiovascular disease was the most common primary disease (75.0%) requiring ECMO treatment, followed by respiratory disease (12.5%). The median duration of ECMO treatment was 7.5 days. Among 16 patients, seven were switched to NM after first using heparin as an anticoagulation agent, and nine received only NM. When comparing aPTT values in the NM group between patients and the ECMO site, that in patients was significantly lower than that at the ECMO site (73.57 vs. 79.25 seconds; P=0.010); in contrast, no difference was observed in the heparin group. Conclusions: NM showed efficacy as a regional anticoagulation method by sustaining a lower aPTT value compared to that measured at the ECMO site. NM should be considered as a safer regional anticoagulation method in VA-ECMO for patients at high risk of bleeding.
Abstract
Background: Anticoagulation during extracorporeal membrane oxygenation (ECMO) usually is required to prevent thrombosis. The aim of this study was to investigate the usefulness of nafamostat mesilate (NM) as a regional anticoagulant during veno-arterial ECMO (VA-ECMO) treatment. Methods: We retrospectively reviewed the medical records of 16 patients receiving VA-ECMO and NM from January 2017 to June 2020 at Haeundae Paik Hospital. We compared clinical and laboratory data, including activated partial thromboplastin time (aPTT), which was measured simultaneously in patients and the ECMO site, to estimate the efficacy of regional anticoagulation. Results: The median patient age was 68.5 years, and 56.3% of patients were men. Cardiovascular disease was the most common primary disease (75.0%) requiring ECMO treatment, followed by respiratory disease (12.5%). The median duration of ECMO treatment was 7.5 days. Among 16 patients, seven were switched to NM after first using heparin as an anticoagulation agent, and nine received only NM. When comparing aPTT values in the NM group between patients and the ECMO site, that in patients was significantly lower than that at the ECMO site (73.57 vs. 79.25 seconds; P=0.010); in contrast, no difference was observed in the heparin group. Conclusions: NM showed efficacy as a regional anticoagulation method by sustaining a lower aPTT value compared to that measured at the ECMO site. NM should be considered as a safer regional anticoagulation method in VA-ECMO for patients at high risk of bleeding.
참고문헌 (28)
- Thiagarajan RR, "Extracorporeal life support organization registry international report 2016", ASAIO J, 63, pp.60~67 (2017)
- Buchtele N, "Anticoagulation in critically ill adults during extracorporeal circulation", Hamostaseologie, 41, pp.294~306 (2021)
- Esper SA, "Extracorporeal membrane oxygenation in the adult : a review of anticoagulation monitoring and transfusion", Anesth Analg, 118, pp.731~743 (2014)
- Olson SR, "Thrombosis and bleeding in extracorporeal membrane oxygenation(ECMO)without anticoagulation : a systematic review", ASAIO J, 67, pp.290~296 (2021)
- Protti A, "Anticoagulation management and antithrombin supplementation practice during veno-venous extracorporeal membrane oxygenation : a worldwide survey", Anesthesiology, 132, pp.562~570 (2020)
- Murphy DA, "Extracorporeal membrane oxygenation-hemostatic complications", Transfus Med Rev, 29, pp.90~101 (2015)
- Selleng S, "Heparin-induced thrombocytopenia in cardiac surgery and critically ill patients", Thromb Haemost, 116, pp.843~851 (2016)
- Akizawa T, "Nafamostat mesilate : a regional anticoagulant for hemodialysis in patients at high risk for bleeding", Nephron, 64, pp.376~381 (1993)
- Sadahiro T, "Current practices in acute blood purification therapy in Japan and topics for further study", Contrib Nephrol, 196, pp.209~214 (2018)
- Makino S, "Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy", Int J Artif Organs, 39, pp.16~21 (2016)
- Choi JY, "Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial", Medicine(Baltimore), 94, pp.e2392~ (2015)
- Kumar G, "Anticoagulation in ECMO patients : an overview", Indian J Thorac Cardiovasc Surg, 37(Suppl 2), pp.241~247 (2021)
- Buscher H, "Blood and anticoagulation management in extracorporeal membrane oxygenation for surgical and nonsurgical patients : a single-center retrospective review", J Cardiothorac Vasc Anesth, 31, pp.869~875 (2017)
- 조화진, "Anticoagulation Therapy during Extracorporeal Membrane Oxygenator Support in Pediatric Patients", 전남의대학술지, 53(2), pp.110~117 (2017), 의과학연구소
- Raiten JM, "Anticoagulation and transfusion therapy in patients requiring extracorporeal membrane oxygenation", J Cardiothorac Vasc Anesth, 31, pp.1051~1059 (2017)
- Muntean W, "Coagulation and anticoagulation in extracorporeal membrane oxygenation", Artif Organs, 23, pp.979~983 (1999)
- Oliver WC, "Anticoagulation and coagulation management for ECMO", Semin Cardiothorac Vasc Anesth, 13, pp.154~175 (2009)
- Aoyama T, "Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments", Jpn J Pharmacol, 35, pp.203~227 (1984)
- Hwang SD, "Nafamostat mesilate for anticoagulation in continuous renal replacement therapy", Int J Artif Organs, 36, pp.208~216 (2013)
- Uchiba M, "Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity", Thromb Res, 74, pp.155~161 (1994)
- Hitomi Y, "Inhibitory effect of a new synthetic protease inhibitor(FUT-175)on the coagulation system", Haemostasis, 15, pp.164~168 (1985)
- Baek NN, "The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding", Ren Fail, 34, pp.279~285 (2012)
- Maruyama Y, "Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis : a three-year retrospective cohort study", Int J Artif Organs, 34, pp.571~576 (2011)
- Han W, "Single-center experience of extracorporeal membrane oxygenation mainly anticoagulated with nafamostat mesilate", J Thorac Dis, 11, pp.2861~2867 (2019)
- Park JH, "Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation", Int J Artif Organs, 38, pp.595~599 (2015)
- Kikuchi M, "Inhibitory effect of FUT-175 on the production of interleukin 8 and polymorphonuclear leukocyte elastase", Res Commun Mol Pathol Pharmacol, 87, pp.269~274 (1995)
- Yoshikawa T, "Effects of FUT-175, a new synthetic protease inhibitor on endotoxin-induced disseminated intravascular coagulation in rats", Haemostasis, 13, pp.374~378 (1983)
- Kamijo H, "Nafamostat mesylate improved survival outcomes of sepsis patients who underwent blood purification : a nationwide registry study in Japan", J Clin Med, 9, pp.2629~ (2020)